Key result
Higher early plasma Ang-2 in sepsis is linked to ~52% greater mortality per log increase.
Why the study?
Elevated circulating Angiopoietin-2 levels may identify critically ill sepsis patients at risk for ARDS and poor clinical outcomes, but this association needed evaluation.
Is early plasma Angiopoietin-2 associated with the development of ARDS and 30-day mortality in critically ill patients with sepsis?
Population
757 critically ill patients with sepsis including 267 with ARDS enrolled early in hospitalization
Comparison
Plasma Angiopoietin-2 levels measured early after hospitalization
Design
Cohort study
Follow-up
30-day
Authors
Loading...
Ang-2 may refine mortality risk prediction in sepsis; leaves open its utility for guiding therapy or ARDS prevention.
Cohort (n=757)
No
Is early plasma Angiopoietin-2 associated with the development of ARDS and 30-day mortality in critically ill patients with sepsis?
Odds Ratio: 1.52 (95% CI 1.28–1.8)
p-value: p=<0.001
Early plasma Ang-2 levels in sepsis patients are prognostic for the development of ARDS and 30-day mortality, highlighting its potential as a biomarker for risk prediction and targeted therapy.
Rosenberger et al. (2023) conducted a cohort in Sepsis (n=757). Early plasma angiopoietin-2 (Ang-2) vs. Lower Ang-2 levels was evaluated on 30-day mortality (OR 1.52, 95% CI 1.28-1.80, p=<0.001). Higher early plasma angiopoietin-2 levels in critically ill patients with sepsis were significantly associated with increased 30-day mortality (OR 1.52 per log Ang-2 increase).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: